RICHMOND, British Columbia, Sept. 23, 2005 (PRIMEZONE) -- BioCurex, Inc. (Pink Sheets:BOCX), a biotechnology company, is pleased to announce it has formalized a relationship with J.P. Turner & Company, L.L.C. to assist the Company with market awareness and provide business advisory services. J.P. Turner, headquartered in Atlanta, is one of the nation's fastest growing full service brokerage firms with over 120 offices from coast-to-coast. J.P. Turner will provide BioCurex with introductions to other broker dealers, research analysts, and investment companies that J.P. Turner believes could be helpful to the Company and its shareholders. Among other services that J.P. Turner will provide to BioCurex, Turner will assist the Company with the identification and evaluation of potential acquisition candidates. The engagement is for 12 months
Dr. Gerald Wittenberg, Director, stated: "Their breadth of services and geographic reach will support numerous opportunities for the Company. We are looking forward to their assistance and introductions to the financial community as we progress in our licensing efforts for our RECAF based blood tests and future imaging and therapeutic applications. We recognize the value of J.P. Turner and their experience in the support of our initiatives. Expanding our exposure in the investment community with a well-known corporation such as J.P. Turner will be of considerable value as we move forward to achieve our corporate goals."
About BioCurex
BioCurex is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section on our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.